Bioactivity | JTV-519 (K201) is a Ca2+-dependent blocker of sarcoplasmic reticulum Ca2+-stimulated ATPase (SERCA) and a partial agonist of ryanodine receptors in striated muscle. Antiarrhythmic and cardioprotective properties[1][2]. |
Invitro | JTV-519 (K201) 以剂量依赖的方式抑制由膜联蛋白 V 引起的 Ca2+ 向内移动到大单层囊泡 (LUV)。在 50 nM 膜联蛋白 V 和 400 μM Ca2+ 存在的情况下,3 μM JTV-519 对 Ca2+ 的抑制作用显著,25 μM K201 的抑制作用达到 50%[2]。 |
In Vivo | JTV-519 (0.5mg/kg/h,术前 2 h 静脉注射) 可改善 CLP 小鼠的心功能,其中与未经 JTV-519 处理的 CLP 小鼠相比,分数缩短 (FS) 和射血分数 (EF) 显著增加[3]。 Animal Model: |
Name | JTV-519 |
CAS | 1038410-88-6 |
Formula | C25H33ClN2O2S |
Molar Mass | 461.06 |
Transport | Room temperature in continental US; may vary elsewhere. |
Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
Reference | [1]. Darcy YL, et al. K201 (JTV519) is a Ca2+-Dependent Blocker of SERCA and a Partial Agonist of Ryanodine Receptors in Striated Muscle. Mol Pharmacol. 2016 Aug;90(2):106-15. [2]. Kaneko N, et al. Inhibition of annexin V-dependent Ca2+ movement in large unilamellar vesicles by K201, a new 1,4-benzothiazepine derivative. Biochim Biophys Acta. 1997 Nov 13;1330(1):1-7. [3]. Yang J, et al. Toll-like receptor 4-induced ryanodine receptor 2 oxidation and sarcoplasmic reticulum Ca2+ leakage promote cardiac contractile dysfunction in sepsis. J Biol Chem. 2018 Jan 19;293(3):794-807. |